Truscreen Opto-electrical Technology Recognised

NZX/ASX Announcement

2 August 2023

TruScreen opto-electrical technology recognized in China Cervical Cancer Screening Guideline by top national expert organisation

Highlights
• China published the First national medical guideline in the world that recognises TruScreen technology
• China Cervical Cancer Screening Guideline (Guideline) of Chinese Society for Colposcopy and Cervical Pathology (CSCCP) recognises TruScreen technology in section “Other Cervical Cancer Screening Methods”
• The Guideline recognises TruScreen technology as the only AI enabled method for cervical cancer screening in China

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that the CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Guideline published in the July edition of CSCCP’s journal recognised TruScreen technology in the Chinese Journal of Clinical Gynaecology and Obstetrics in July 2023.

The formal publication follows from media announcement at major national congress of CSCCP in Beijing in May 2023.

CSCCP’s decision to include TruScreen technology in its new Guideline emphasises the role of new technology in the booming Chinese healthcare sector that focuses on AI and digitalisation of medical processes and practices. The decision is based on the body of evidence supporting TruScreen clinical use gathered in China and world-wide. The decision was also made after extensive consultations with healthcare practitioners and decision makers.

CSCCP is a member of IFCPC (The International Federation of Cervical Pathology and Colposcopy) which is dedicated to reducing the incidence of cervical cancer worldwide through the focus on basic and applied research, sharing of knowledge surrounding appropriate fields, and standardization of terminology in the field of cervical pathology. The guideline issued by CSCCP is a leading clinical standard for doctors and other healthcare clinicians and government agencies.

CEO, Dr Beata Edling commented:
“I am delighted to see TruScreen reaching this important technology acceptance milestone. The CSCCP recognition of TruScreen’s technology strengthens opportunities for transforming cervical cancer screening worldwide and will have a positive impact on our sales and marketing in the coming years.”

This announcement has been approved by the Board.

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
[email protected]
Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF